Diskussionsleiter: B. Lauer (Bad Berka)
| (P1442) | Impact of Chronic Kidney Disease on Outcomes in Patients Undergoing Transfemoral TAVI with Bivalirudin or Unfractionated Heparin: Results from the BRAVO 3 Trial | |
| C. Hengstenberg, T. Lefevre, C. Kupatt, U. Schäfer, A. Linke, O. Husser, E. Grube, P. Boekstegers, R. Mehran, P. Anthopoulos, G. Dangas , BRAVO (München, Hamburg, Leipzig, Bonn, Siegburg; Massy, FR; New York, NY, US; Zürich, CH) | ||
| (P1443) | Akute and chronic kidney injury in patients undergoing aortic valve implantation exclusively transfemoral in local anesthesia without general anesthesia or deep sedation | |
| S. Fateh-Moghadam, P. Htun, M. Droppa, T. Geisler, M. Gawaz, W. Bocksch (Tübingen) | ||
| (P1444) | Kann TAVI der neue Standard in der Behandlung der Aortenstenose bei Dialysepatienten werden? | |
| H. Weiler, S. Büttner, C. Zöller, A. Zierer, T.-L. B. Luu, J. Honold, F. Seeger, C. Betz, A. Moritz, H. Geiger, A. M. Zeiher, S. Fichtlscherer (Frankfurt am Main) | ||
| (P1445) | Transcatheter aortic valve implantation in patients with an active cancer disease | |
| N. Mangner, F. Woitek, R. Höllriegel, S. Haussig, F. Schlotter, G. Stachel, A. Lindner, S. Leontyev, D. Holzhey, F. W. Mohr, G. C. Schuler, A. Linke (Leipzig) | ||
| (P1446) | Risk Assessment of Patients Undergoing Transfemoral Aortic Valve Implantation upon Admission for postinterventional Intensive Care and Surveillance: Implications on Short- and Midterm Outcome. | |
| F. Al-Rashid, P. Kahlert, H. A. Hildebrandt, F. Selge, P. C. Patsalis, M. Totzeck, D. Wendt, M. Thielmann, H. G. Jakob, T. Rassaf, R. A. Jánosi (Essen) | ||
| (P1447) | Short – and Long- term clinical outcomes after transapical Transcatheter Aortic Valve Implantation (TAVI) in Patients with chronic renal failure. | |
| M. Abdulghafor, D. Wendt, M. Thielmann, B. Hailer, H. G. Jakob, J. Benedik, B. Humaid (Essen) |